Christopher J D Wallis,, Frcsc

List of Publications by Citations

121 papers	1,823 citations	21 h-index	40 g-index
160 ext. papers	2,576 ext. citations	5.2 avg, IF	5.07 L-index

#	Paper	IF	Citations
121	Comparison of postoperative outcomes among patients treated by male and female surgeons: a population based matched cohort study. *BMJ, The*, **2017**, 359, j4366	5.9	233
120	Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. *European Urology*, **2016**, 70, 21-30	10.2	146
119	Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. *BMJ, The*, **2016**, 352, i851	5.9	126
118	Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2019**, 5, 529-536	13.4	109
117	Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 498-506	18.1	101
116	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. *European Urology*, **2020**, 78, 29-42	10.2	71
115	Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. *European Urology*, **2018**, 73, 834-844	10.2	56
114	The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. *BJU International*, **2018**, 121, 684-698	5.6	49
113	Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. *European Urology*, **2018**, 73, 11-20	10.2	48
112	MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence. *Prostate*, **2016**, 76, 869-84	4.2	45
111	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. *European Urology*, **2018**, 74, 309-321	10.2	40
110	A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population. *Journal of Urology*, **2016**, 196, 361-6	2.5	35
109	First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. *European Urology Oncology*, **2019**, 2, 708-715	6.7	34
108	Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?. *European Urology Oncology*, **2019**, 2, 365-378	6.7	30
107	Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study. *Journal of Cancer*, **2015**, 6, 1160-71	4.5	26
106	Cancer diagnosis and risk of suicide after accounting for prediagnosis psychiatric care: A matched-cohort study of patients with incident solid-organ malignancies. *Cancer*, **2019**, 125, 2886-2895	6.4	24
105	Establishing the Effectiveness of Procedural Interventions: The Limited Role of Randomized Trials. *JAMA - Journal of the American Medical Association*, **2018**, 320, 2421-2422	27.4	24

104	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. *European Urology*, **2020**, 78, 731-742	10.2	23
103	Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. *JAMA - Journal of the American Medical Association*, **2017**, 318, 1260-1271	27.4	21
102	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. *European Urology Oncology*, **2018**, 1, 238-241	6.7	21
101	MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL. *Prostate*, **2019**, 79, 1422-1438	4.2	21
100	The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis. *JAMA Internal Medicine*, **2017**, 177, 1273-1286	11.5	21
99	Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis. *Urology*, **2015**, 85, 621-7	1.6	21
98	Twitter and academic Urology in the United States and Canada: a comprehensive assessment of the Twitterverse in 2019. *BJU International*, **2020**, 125, 173-181	5.6	21
97	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. *Clinical Genitourinary Cancer*, **2020**, 18, 343-350	3.3	20
96	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. *Journal of Urology*, **2020**, 203, 1085-1093	2.5	20
95	MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells. *Oncotarget*, **2018**, 9, 19159-19176	5.3	19
94	The impact of psychiatric utilisation prior to cancer diagnosis on survival of solid organ malignancies. *British Journal of Cancer*, **2019**, 120, 840-847	8.7	18
93	Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis. *Clinical Genitourinary Cancer*, **2018**, 16, 206-212.e1	3.3	18
92	Occurrence of and Risk Factors for Urological Intervention During Benign Hysterectomy: Analysis of the National Surgical Quality Improvement Program Database. *Urology*, **2016**, 97, 66-72	1.6	18
91	Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation. *Urology*, **2016**, 97, 145-152	1.6	17
90	Role of mpMRI of the prostate in screening for prostate cancer. *Translational Andrology and Urology*, **2017**, 6, 464-471	2.3	16
89	Effect of radical prostatectomy surgeon volume on complication rates from a large population-based cohort. *Canadian Urological Association Journal*, **2016**, 10, 45-9	1.2	16
88	Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?. *PLoS ONE*, **2019**, 14, e0216255	3.7	15
87	Platelet to white blood cell ratio predicts 30-day postoperative infectious complications in patients undergoing radical nephrectomy for renal malignancy. *Canadian Urological Association Journal*, **2017**, 11, E414-E420	1.2	15

86	Morbidity and Mortality of Radical Nephrectomy for Patients With Disseminated Cancer: An Analysis of the National Surgical Quality Improvement Program Database. *Urology*, **2016**, 95, 95-102	1.6	15
85	Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines. *Journal of Urology*, **2018**, 199, 906-914	2.5	14
84	The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity. *Cancer*, **2019**, 125, 1050-1059	6.4	14
83	Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape. *OncoTargets and Therapy*, **2020**, 13, 3571-3581	4.4	13
82	New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men. *European Urology*, **2016**, 69, 933-41	10.2	11
81	Association of Surgeon-Patient Sex Concordance With Postoperative Outcomes. *JAMA Surgery*, **2021**,	5.4	11
80	Identification of a Novel MicroRNA Panel Associated with Metastasis Following Radical Prostatectomy for Prostate Cancer. *Anticancer Research*, **2018**, 38, 5027-5034	2.3	11
79	A Population-Based Assessment of Urologic Procedures and Operations After Surgery or Pelvic Radiation for Cervical Cancer. *International Journal of Gynecological Cancer*, **2018**, 28, 989-995	3.5	9
78	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 603.e17-603.e25	2.8	8
77	Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2020**, 40, 1-12	7.1	8
76	Association Between Primary Local Treatment and Non-prostate Cancer Mortality in Men With Nonmetastatic Prostate Cancer. *Urology*, **2018**, 114, 147-154	1.6	8
75	Desmopressin and the risk of hyponatremia: A population-based cohort study. *PLoS Medicine*, **2019**, 16, e1002930	11.6	8
74	Prostate Cancer Genetics: A Review. *Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine*, **2015**, 26, 79-91	2.4	8
73	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. *World Journal of Urology*, **2020**, 38, 2547-2554	4	8
72	Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer-The Forgotten Dance Partner?. *JAMA Oncology*, **2019**, 5, 144-145	13.4	8
71	Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. *Japanese Journal of Clinical Oncology*, **2020**, 50, 800-809	2.8	6
70	The cost of intraoperative adverse events in abdominal and pelvic surgery: A systematic review. *American Journal of Surgery*, **2018**, 215, 163-170	2.7	6
69	Assessing patient risk from cancer and COVID-19: Managing patient distress. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 243-246	2.8	6

68	Perioperative venous thromboembolism prophylaxis in prostate cancer surgery. *World Journal of Urology*, **2020**, 38, 593-600	4	6
67	Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. *European Urology*, **2019**, 75, 3-7	10.2	5
66	Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials. *Cancer*, **2021**, 127, 709-719	6.4	5
65	The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation. *British Journal of Cancer*, **2018**, 118, 1399-1405	8.7	5
64	Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients - A Cross Sectional Study. *Urology*, **2019**, 134, 154-162	1.6	4
63	Estimating the effect of immortal-time bias in urological research: a case example of testosterone-replacement therapy. *BJU International*, **2017**, 120, 584-590	5.6	3
62	ProtecTion from overtreatment: does a randomized trial finally answer the key question in localized prostate cancer?. *BJU International*, **2017**, 119, 513-514	5.6	3
61	Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. *New England Journal of Medicine*, **2019**, 380, 2581	59.2	3
60	Radical cystectomy in patients with disseminated disease: An assessment of perioperative outcomes using the National Surgical Quality Improvement Program database. *Canadian Urological Association Journal*, **2017**, 11, 244-248	1.2	3
59	Peripheral Nerve Injury during Abdominal-Pelvic Surgery: Analysis of the National Surgical Quality Improvement Program Database. *American Surgeon*, **2017**, 83, 1214-1219	0.8	3
58	Anticholinergics for overactive bladder: Temporal trends in prescription and treatment persistence. *Canadian Urological Association Journal*, **2016**, 10, 277-280	1.2	3
57	Hospitalizations to Manage Complications of Modern Prostate Cancer Treatment in Older Men. *Urology*, **2016**, 96, 142-147	1.6	3
56	Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study. *Urology*, **2018**, 113, 138-145	1.6	3
55	Predictors of prostate-specific antigen testing in men aged ≥55 years: A cross-sectional study based on patient-reported outcomes. *International Journal of Urology*, **2020**, 27, 711-718	2.3	2
54	Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis. *MDM Policy and Practice*, **2017**, 2, 2381468317709476	1.5	2
53	Testosterone deficiency syndrome and cardiovascular health: An assessment of beliefs, knowledge and practice patterns of general practitioners and cardiologists in Victoria, BC. *Canadian Urological Association Journal*, **2014**, 8, 30-3	1.2	2
52	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.. *Journal of Clinical Oncology*, **2020**, 38, 131-131	2.2	2
51	Re-operation within 30 days of radical cystectomy: Identifying high-risk patients and complications using American College of Surgeons National Surgical Quality Improvement Program database. *Canadian Urological Association Journal*, **2021**, 15, E1-E5	1.2	2

50	Trends in medicare spending across strata of resource utilization among older individuals in the United States. *EClinicalMedicine*, **2021**, 36, 100873	11.3	2
49	Survival and peri-operative outcomes among patients with rectal cancer: the role of prior radiotherapy due to prostate cancer. *International Journal of Colorectal Disease*, **2019**, 34, 97-104	3	2
48	Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer.. *JNCI Cancer Spectrum*, **2021**, 5, pkab082	4.6	2
47	Influence of Sociodemographic Factors on Definitive Intervention Among Low-risk Active Surveillance Patients. *Urology*, **2021**, 155, 117-123	1.6	2
46	Isolated brain metastasis from a small renal mass. *BMJ Case Reports*, **2016**, 2016,	0.9	1
45	Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 241.e1-241.e6	2.8	1
44	Reply to Comment on: "The impact of psychiatric utilisation prior to cancer diagnosis on survival of solid organ malignancies". *British Journal of Cancer*, **2019**, 121, 195-196	8.7	1
43	Re: Comparison of Population-based Observational Studies with Randomized Trials in Oncology. *European Urology*, **2019**, 76, 869-870	10.2	1
42	Variation in clinical practice: forests and trees revisited. *Nature Reviews Urology*, **2017**, 14, 511-512	5.5	1
41	Long-term incidence of venous thromboembolic events following cystectomy: A population-based analysis.. *Journal of Clinical Oncology*, **2017**, 35, 288-288	2.2	1
40	Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes.. *Journal of Urology*, **2022**, 101097JU0000000000002370	2.5	1
39	Medicare Two-Midnight Rule Accelerated Shift To Observation Stays. *Health Affairs*, **2021**, 40, 1688-1696	7	1
38	Adjuvant Versus Salvage Radiotherapy Following Radical Prostatectomy: Meta-analysis of the Effect of Comparator Salvage Approach on Study Conclusions. *European Urology*, **2020**, 77, 395-396	10.2	1
37	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 622-629	6.2	1
36	Population-based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non-metastatic muscle-invasive bladder cancer. *Cancer Medicine*, **2021**, 10, 2636-2644	4.8	1
35	Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. *JAMA Network Open*, **2021**, 4, e2110950	10.4	1
34	Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study. *Cancer*, **2021**, 127, 3156-3162	6.4	1
33	Complications after surgery for benign prostatic enlargement: a population-based cohort study in Ontario, Canada. *BMJ Open*, **2019**, 9, e032170	3	1

32	Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?. *BJU International*, **2021**, 127, 654-664	5.6	1
31	The cost of treatment and its related complications for men who receive surgery or radiation therapy for prostate cancer. *Canadian Urological Association Journal*, **2018**, E236-E248	1.2	1
30	Women as Authors of Randomized Controlled Trials of Minimally Invasive Surgery: Systematic Review and Meta-Analysis of 3 Decades of Trials. *Journal of the American College of Surgeons*, **2021**, 233, 167-175.e9	4.4	1
29	Dissecting the role of radical cystectomy and urinary diversion in post-operative complications: an analysis using the American College of Surgeons national surgical quality improvement program database. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2021**, 47, 1006-1019	2	1
28	RE: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	0
27	Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach. *Cancer Causes and Control*, **2021**, 32, 675-680	2.8	0
26	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. *Urology*, **2021**, 153, 147-155	1.6	0
25	Setting the Standards: Examining Research Productivity Among Academic Urologists in the USA and Canada in 2019. *European Urology Focus*, **2021**, 7, 489-496	5.1	0
24	Is there an association between a history of military service and cancer diagnosis? Results from a US national-level study of self-reported outcomes. *Cancer Causes and Control*, **2021**, 32, 47-55	2.8	0
23	Use of psychotropic drugs among older patients with bladder cancer in the United States. *Psycho-Oncology*, **2021**, 30, 832-843	3.9	0
22	Out-of-pocket costs for commercially insured patients with localized prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 797-805	2.8	0
21	Reply: To PMID 25733275. *Urology*, **2015**, 85, 628	1.6	
20	Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. *Canadian Urological Association Journal*, **2018**, 12, E59-E63	1.2	
19	RE: Rydzewska et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 Oct; 84:88-101. *European Journal of Cancer*, **2018**, 94, 216-217	7.5	
18	Editorial Comment. *Journal of Urology*, **2017**, 198, 1067-1068	2.5	
17	Treatment of Metastatic Hormone-Sensitive Prostate Cancer **2022**, 97-117		
16	Re: Long-term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-based Cohort Study. *European Urology*, **2021**, 81, 119-119	10.2	
15	The impact of pre-cancer (Ca) diagnosis (Dx) psychiatric utilization (PU) on survival in patients with solid organ ca: A population analysis in Ontario, Canada.. *Journal of Clinical Oncology*, **2018**, 36, e22144-e22144	2.2	

14	Editorial Comment. *Journal of Urology*, **2020**, 203, 758-759	2.5
13	Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.. *Journal of Clinical Oncology*, **2020**, 38, 9552-9552	2.2
12	Reply by Authors. *Journal of Urology*, **2020**, 203, 1093	2.5
11	Comment on "Responsibilities and Expectations: Considerations of Disclosure of Overlapping Operations". *Annals of Surgery*, **2021**, 274, e725-e726	7.8
10	Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2017**, 35, 252-252	2.2
9	Absence of a positive outcome bias in randomized controlled trials of minimally invasive surgical techniques. *Journal of Clinical Epidemiology*, **2021**, 131, 163-165	5.7
8	Transparency of racial participation reporting in randomized controlled trials of minimally invasive surgical techniques. *Surgical Endoscopy and Other Interventional Techniques*, **2021**, 1	5.2
7	Stress Incontinence Surgery Does Not Cause Pelvic Malignancy: A Population-Based Cohort Study. *Journal of Urology*, **2021**, 205, 1725-1732	2.5
6	Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 40, 56.e1-56.e1	2.8
5	EDITORIAL COMMENT. *Urology*, **2021**, 147, 160-161	1.6
4	Real-world utilization of docetaxel among men with de novo metastatic castration-sensitive prostate cancer: A population-based study in men aged 66 or older.. *Journal of Clinical Oncology*, **2021**, 39, 47-47	2.2
3	Geographic variation in systemic therapy in men age 66 years and older with de novo metastatic castration-sensitive prostate cancer: A population-based study in a single payer health-system.. *Journal of Clinical Oncology*, **2021**, 39, 50-50	2.2
2	Response to Claire Vale, David Fisher, Jayne Tierney, Ian White, Matthew Sydes, and James Carpenter☹ Letter to the Editor re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. [illegible] **2018**, 73, e51	10.2
1	Patterns of care for patients with non-metastatic castration-resistant prostate cancer: Population-based study in Ontario, Canada.. *Journal of Clinical Oncology*, **2022**, 40, 53-53	2.2